2016
DOI: 10.1016/j.nano.2016.06.002
|View full text |Cite
|
Sign up to set email alerts
|

Antimicrobial molecular nanocarrier–drug conjugates

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
28
0
3

Year Published

2018
2018
2022
2022

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 34 publications
(31 citation statements)
references
References 166 publications
0
28
0
3
Order By: Relevance
“…The dose and size dependent inhibitory effects of Ox nanocarriers against bacterial strains could be attributed to the combination of several factors such as their permeability into the bacterial cells and the efflux function of membrane transporters in extruding nanocarriers out of cells. 22,64 We have observed Ox nanocarriers inside the cells and have used Ox nanocarriers to study the efflux function of ABC transporters in single live cells. 65 Further studies are needed to depict the underlying molecular mechanisms.…”
Section: Size-dependent Lamentation Of E Coli Using Single Live Celmentioning
confidence: 99%
See 1 more Smart Citation
“…The dose and size dependent inhibitory effects of Ox nanocarriers against bacterial strains could be attributed to the combination of several factors such as their permeability into the bacterial cells and the efflux function of membrane transporters in extruding nanocarriers out of cells. 22,64 We have observed Ox nanocarriers inside the cells and have used Ox nanocarriers to study the efflux function of ABC transporters in single live cells. 65 Further studies are needed to depict the underlying molecular mechanisms.…”
Section: Size-dependent Lamentation Of E Coli Using Single Live Celmentioning
confidence: 99%
“…Polymer-based NPs have been used to increase the drug payload and to increase the efficacy of therapeutic agents. [22][23][24][25] Other NPs themselves have showed inhibitory effects against bacteria. 26,27 However, the dependence of their efficacy and inhibitory effects upon their physicochemical properties has not yet been systematically studied, which hinders rational design of drug nanocarriers to effectively overcome MDR and to effectively achieve their maximum efficacy.…”
Section: Introductionmentioning
confidence: 99%
“…[1][2][3] Similarly,i ti si mportant for prodrug strategies aiming to minimize systemic adverse effects and to improvet he pharmacokinetics of ac ompound. [1][2][3] Similarly,i ti si mportant for prodrug strategies aiming to minimize systemic adverse effects and to improvet he pharmacokinetics of ac ompound.…”
Section: Introductionmentioning
confidence: 99%
“…The controlled releaseo fb ioactive compounds in at emporal and spatialm anner upon as pecific trigger is ak ey issue for the development of targeted drug conjugatesi no rder for the drug to display its biological activity in the targeted cell only. [1][2][3] Similarly,i ti si mportant for prodrug strategies aiming to minimize systemic adverse effects and to improvet he pharmacokinetics of ac ompound. [4][5][6] Furthermore, molecular systems able to release fluorescent molecules upon specific triggering can be appliedi nt he developmento fi maging tools in chemicalb iology.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, the inefficient transport through the cytoplasmic membrane limits an antifungal activity of HONV. One of the possible approaches to solve this problem could be the application of the so‐called Trojan horse strategy, ie, conjugation of an enzyme inhibitor with a molecular nanocarrier . In the case of inhibitors of amino acid structure, facilitated transport is possible after their incorporation into oligopeptides, which are effectively taken up by oligopeptide permeases, demonstrating broad substrate specificity.…”
Section: Introductionmentioning
confidence: 99%